{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:32:41Z","timestamp":1792758761527,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004203","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.biomaterials.2011.10.061","type":"journal-article","created":{"date-parts":[[2011,11,11]],"date-time":"2011-11-11T00:56:03Z","timestamp":1320972963000},"page":"1445-1454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models"],"prefix":"10.1016","volume":"33","author":[{"given":"Mark J.","family":"Ernsting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Lun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah W.","family":"MacCallum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyh-Dar","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2011.10.061_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J\u00a0Pharmacol Toxicol Methods"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib2","first-page":"66","article-title":"Prediction of pharmacokinetics and drug-drug interactions from in\u00a0vitro metabolism data","volume":"8","author":"Shou","year":"2005","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00210785","article-title":"Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein","volume":"14","author":"Urien","year":"1996","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2010.02.029","article-title":"Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles","volume":"144","author":"Zhigaltsev","year":"2010","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jconrel.2011.02.009","article-title":"Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin","volume":"152","author":"Tagami","year":"2011","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib8","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1016\/j.biomaterials.2011.05.029","article-title":"MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome","volume":"32","author":"Tagami","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jconrel.2011.05.020","article-title":"Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a brij surfactant using a robust in\u00a0vitro system","volume":"154","author":"Tagami","year":"2011","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib10","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S1359-6349(06)80002-9","article-title":"Head-to-head: docetaxel challenges paclitaxel","volume":"4","author":"Jones","year":"2006","journal-title":"EJC Supplements"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib12","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(95)90963-X","article-title":"Polysorbate 80 hypersensitivity","volume":"345","author":"Shelley","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejpb.2008.08.003","article-title":"In\u00a0vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles","volume":"71","author":"Letchford","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/annonc\/mdp315","article-title":"Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors","volume":"21","author":"Lim","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2009.11.012","article-title":"Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes","volume":"143","author":"Gaucher","year":"2010","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1593\/neo.07229","article-title":"Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts","volume":"9","author":"Auzenne","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/mp800049w","article-title":"Pharmacokinetics and biodistribution of nanoparticles","volume":"5","author":"Li","year":"2008","journal-title":"Mol Pharm"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib18","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1958","article-title":"Polymer conjugates as anticancer nanomedicines","volume":"6","author":"Duncan","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0169-409X(02)00045-5","article-title":"Poly(L-glutamic acid)\u2013anticancer drug conjugates","volume":"54","author":"Li","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/JTO.0b013e31817c6b68","article-title":"Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer","volume":"3","author":"O\u2019Brien","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s002800000168","article-title":"Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor","volume":"46","author":"Li","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib22","first-page":"143","article-title":"Water-soluble polysaccharide-anthracycline conjugates: biological activity","volume":"7","author":"Cera","year":"1992","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/0-306-47932-X_9","article-title":"CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data","volume":"519","author":"Inoue","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/1078-0432.703.11.2","article-title":"Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors","volume":"11","author":"Soepenberg","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/0883911505059251","article-title":"Biodistribution and antitumor activity induced by carboxymethylcellulose conjugates","volume":"20","author":"Uglea","year":"2005","journal-title":"J\u00a0Bioactive Compatible Polym"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib26","unstructured":"Namikoshi, H. US Patent: Carboxyalkyl acetyl celluloses, their salts and a process for the preparation of them. USPTO; 1985."},{"key":"10.1016\/j.biomaterials.2011.10.061_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/41.1.7678025","article-title":"A\u00a0new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA","volume":"41","author":"Wijsman","year":"1993","journal-title":"J\u00a0Histochem Cytochem"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib28","first-page":"135","article-title":"Structure and properties of pharmacologically active polymers","volume":"51","author":"Ringsdorf","year":"1975","journal-title":"Journal of Polymer Science: Polym Symposia"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/cancers3010017","article-title":"Clinically relevant anticancer polymer paclitaxel therapeutics","volume":"3","author":"Yang","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd1088","article-title":"The dawning era of polymer therapeutics","volume":"2","author":"Duncan","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib31","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1002\/jps.21245","article-title":"Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel","volume":"97","author":"Liu","year":"2008","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib32","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1021\/nn900649v","article-title":"HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors","volume":"3","author":"Wang","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib33","first-page":"2404","article-title":"Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate","volume":"58","author":"Li","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jconrel.2006.10.009","article-title":"Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992)","volume":"117","author":"Sugahara","year":"2007","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib35","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1158\/1078-0432.CCR-06-2362","article-title":"A\u00a0physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man","volume":"13","author":"Bradshaw-Pierce","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/(SICI)1097-4636(199607)31:3<401::AID-JBM15>3.0.CO;2-L","article-title":"Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice","volume":"31","author":"Fernandez-Urrusuno","year":"1996","journal-title":"J\u00a0Biomed Mater Res"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib37","doi-asserted-by":"crossref","DOI":"10.1021\/bc200284b","article-title":"Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells","author":"Ernsting","year":"2011","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1023\/A:1008245400251","article-title":"Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere)","volume":"8","author":"Hilkens","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib39","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.addr.2007.11.009","article-title":"Polymer-drug conjugates: recent development in clinical oncology","volume":"60","author":"Li","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib40","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2011.10.061_bib41","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity,\u00a0intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961211012774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961211012774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:35:24Z","timestamp":1758900924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961211012774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0142961211012774"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2011.10.061","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2011.10.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}